Pharmacokinetics, Dialysability and Safety of P03277, a New Gadolinium-based Contrast Agent, in Healthy Volunteers and in Patients With Impaired Renal Function
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Gadopiclenol (Primary)
- Indications CNS disorders; Kidney disorders; Liver cancer
- Focus Pharmacokinetics
- Sponsors Guerbet
- 14 Feb 2019 Planned End Date changed from 30 Jun 2019 to 25 Sep 2019.
- 14 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2018 New trial record